Ipsen S.A. (IPSEY) Research

Ipsen S.A. operates as a global biopharmaceutical company, specializing in the research, development, and marketing of innovative medicines. Its therapeutic focus areas encompass oncology, neuroscience, gastroenterology, cognitive disorders, and various rare diseases. The company's diverse product portfolio includes significant oncology treatments like Somatuline, prescribed for neuroendocrine tumors and acromegaly; Decapeptyl, utilized for advanced metastatic prostate cancer; Cabometyx, targeting renal cell and second-line hepatocellular carcinoma; and Onivyde, for second-line metastatic pancreatic cancer. In neuroscience and endocrine care, Ipsen offers Dysport for motor muscular disorders and cosmetic applications, alongside NutropinAq and Increlex, both aimed at addressing growth failure in children and adolescents, with NutropinAq also indicated for adult growth hormone deficiency, Turner syndrome, and chronic renal failure. For gastrointestinal health, key products include Smecta for chronic and acute diarrhea as well as pain from functional bowel diseases; Forlax for constipation; and Fortrans/Eziclen for bowel preparation before medical procedures such as endoscopy, X-ray examinations, and colonic surgery. Tanakan is available for adults experiencing cognitive disorders, vestibular vertigo, vestibular rehabilitation, and tinnitus. Additional specialized offerings consist of Xermelo for carcinoid syndrome, Cometriq for medullary thyroid cancer, and Etiasa for inflammatory bowel diseases. Ipsen also provides consumer healthcare solutions like the Smebiocta/SmectaFlora Protect food supplement and SmectaGas, a medical device for the symptomatic treatment of gas-related digestive issues. Furthermore, its consumer healthcare segment features other gastrointestinal products such as Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. maintains strategic partnerships and agreements with numerous entities, including Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, Schwabe, BAKX Therapeutics Inc., and Exicure. The company was founded in 1929 and its corporate headquarters are located in Boulogne-Billancourt, France.

Open Ipsen S.A. (IPSEY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.